Please assess the completion status of the following clinical trial:

Trial Title: Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical~1. Patients with angina and documented ischemia or patients with documented silent ischemia~2. Patients who are eligible and has been successfully applied for DES implantation~3. Age \>18 years~4. Signed written informed consent form prior to study entry~2. Angiographic~1. De novo lesion or restenotic lesions~2. Percent diameter stenosis ≥50%~3. Reference vessel size 2.5 mm by visual estimation~Exclusion Criteria:~1. History of bleeding diathesis or coagulopathy (e.g. current use of NSAIDs, Upper GI bleeding during the recent 6 months)~2. Pregnancy or lactation (women who have child-bearing potential)~3. Known hypersensitivity or contra-indication to contrast agent, heparin, eluted-drug of stent~4. Limited life-expectancy (less than 1 year) due to combined serious disease~5. Characteristics of lesion 1)Left main disease 2)Graft vessels~6. Hematological disease (Neutropenia \<3000/mm3, Thrombocytopenia \<100,000/mm3)~7. Hepatic dysfunction, liver enzyme (ALT and AST) elevation 3 times normal~8. Renal dysfunction, creatinine 2.0mg/dL~9. Contraindication to aspirin, clopidogrel or cilostazol~10. Stroke (ischemic or hemorrhagic) or transient ischemic attack (TIA) within 6 months.~11. Planned major surgery within the next 6 months with the need to discontinue antiplatelet therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cilostazol (Type: EXPERIMENTAL): cilostazol 100mg
- dual therapy group (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).